Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome

John D DiBaise

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

After the 1-to 2-year period of greatest intestinal adaptation following massive resection, a homeostatic/maintenance stage begins where no further spontaneous intestinal adaptation is thought to occur. Intestinal failure is frequently considered permanent when parenteral nutrition (PN) is required beyond this stage. This is exemplified by the <6% probability of eliminating PN use if not successfully accomplished in the first 2 years after the individual’s last bowel resection [1]. Fortunately, >50% of adults with SBS are able to be weaned completely from PN within 5 years of diagnosis [1,2]. Despite the life-saving nature of PN and advances in its provision, it is associated with significant risks to the patient, such as catheter-related sepsis, venous thrombosis, and liver disease; notably, it also impairs quality of life and is very costly. Therefore, an important goal when treating the SBS patient who requires PN is to reduce dependency on it and, whenever possible, eliminate its use altogether. As such, there has been intense investigation to identify treatments that maximize intestinal adaptation and absorption.

Original languageEnglish (US)
Title of host publicationShort Bowel Syndrome
Subtitle of host publicationPractical Approach to Management
PublisherCRC Press
Pages249-262
Number of pages14
ISBN (Electronic)9781498720809
ISBN (Print)9781498720786
DOIs
StatePublished - Jan 1 2017

Fingerprint

Short Bowel Syndrome
Parenteral Nutrition
Growth Hormone
Small Intestine
Intestinal Absorption
Venous Thrombosis
Liver Diseases
Sepsis
Catheters
Maintenance
Quality of Life

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DiBaise, J. D. (2017). Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome. In Short Bowel Syndrome: Practical Approach to Management (pp. 249-262). CRC Press. https://doi.org/10.1201/b20188

Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome. / DiBaise, John D.

Short Bowel Syndrome: Practical Approach to Management. CRC Press, 2017. p. 249-262.

Research output: Chapter in Book/Report/Conference proceedingChapter

DiBaise, JD 2017, Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome. in Short Bowel Syndrome: Practical Approach to Management. CRC Press, pp. 249-262. https://doi.org/10.1201/b20188
DiBaise JD. Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome. In Short Bowel Syndrome: Practical Approach to Management. CRC Press. 2017. p. 249-262 https://doi.org/10.1201/b20188
DiBaise, John D. / Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome. Short Bowel Syndrome: Practical Approach to Management. CRC Press, 2017. pp. 249-262
@inbook{665619d40b734a38a1ad11b5b8b60cf7,
title = "Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome",
abstract = "After the 1-to 2-year period of greatest intestinal adaptation following massive resection, a homeostatic/maintenance stage begins where no further spontaneous intestinal adaptation is thought to occur. Intestinal failure is frequently considered permanent when parenteral nutrition (PN) is required beyond this stage. This is exemplified by the <6{\%} probability of eliminating PN use if not successfully accomplished in the first 2 years after the individual’s last bowel resection [1]. Fortunately, >50{\%} of adults with SBS are able to be weaned completely from PN within 5 years of diagnosis [1,2]. Despite the life-saving nature of PN and advances in its provision, it is associated with significant risks to the patient, such as catheter-related sepsis, venous thrombosis, and liver disease; notably, it also impairs quality of life and is very costly. Therefore, an important goal when treating the SBS patient who requires PN is to reduce dependency on it and, whenever possible, eliminate its use altogether. As such, there has been intense investigation to identify treatments that maximize intestinal adaptation and absorption.",
author = "DiBaise, {John D}",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/b20188",
language = "English (US)",
isbn = "9781498720786",
pages = "249--262",
booktitle = "Short Bowel Syndrome",
publisher = "CRC Press",

}

TY - CHAP

T1 - Utility of growth hormone and other potential agents to restore enteral autonomy in short bowel syndrome

AU - DiBaise, John D

PY - 2017/1/1

Y1 - 2017/1/1

N2 - After the 1-to 2-year period of greatest intestinal adaptation following massive resection, a homeostatic/maintenance stage begins where no further spontaneous intestinal adaptation is thought to occur. Intestinal failure is frequently considered permanent when parenteral nutrition (PN) is required beyond this stage. This is exemplified by the <6% probability of eliminating PN use if not successfully accomplished in the first 2 years after the individual’s last bowel resection [1]. Fortunately, >50% of adults with SBS are able to be weaned completely from PN within 5 years of diagnosis [1,2]. Despite the life-saving nature of PN and advances in its provision, it is associated with significant risks to the patient, such as catheter-related sepsis, venous thrombosis, and liver disease; notably, it also impairs quality of life and is very costly. Therefore, an important goal when treating the SBS patient who requires PN is to reduce dependency on it and, whenever possible, eliminate its use altogether. As such, there has been intense investigation to identify treatments that maximize intestinal adaptation and absorption.

AB - After the 1-to 2-year period of greatest intestinal adaptation following massive resection, a homeostatic/maintenance stage begins where no further spontaneous intestinal adaptation is thought to occur. Intestinal failure is frequently considered permanent when parenteral nutrition (PN) is required beyond this stage. This is exemplified by the <6% probability of eliminating PN use if not successfully accomplished in the first 2 years after the individual’s last bowel resection [1]. Fortunately, >50% of adults with SBS are able to be weaned completely from PN within 5 years of diagnosis [1,2]. Despite the life-saving nature of PN and advances in its provision, it is associated with significant risks to the patient, such as catheter-related sepsis, venous thrombosis, and liver disease; notably, it also impairs quality of life and is very costly. Therefore, an important goal when treating the SBS patient who requires PN is to reduce dependency on it and, whenever possible, eliminate its use altogether. As such, there has been intense investigation to identify treatments that maximize intestinal adaptation and absorption.

UR - http://www.scopus.com/inward/record.url?scp=85053989401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053989401&partnerID=8YFLogxK

U2 - 10.1201/b20188

DO - 10.1201/b20188

M3 - Chapter

AN - SCOPUS:85053989401

SN - 9781498720786

SP - 249

EP - 262

BT - Short Bowel Syndrome

PB - CRC Press

ER -